Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-5T4/MMAE antibody-drug conjugate XB010

An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against the oncofetal antigen 5T4 conjugated to the auristatin derivative and microtubule-disrupting cytotoxic agent monomethyl auristatin E (MMAE), with potential antineoplastic activity. Upon administration of anti-5T4/MMAE ADC XB010, the anti-5T4 antibody moiety selectively binds to tumor cells expressing 5T4. Upon binding and internalization, MMAE binds to tubulin and inhibits its polymerization, which results in G2/M phase arrest and induces apoptosis in 5T4-expressing tumor cells. 5T4, a transmembrane glycoprotein, is overexpressed by a variety of cancer cell types while its expression is limited in normal adult tissues; its expression is correlated with increased invasiveness.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-5T4 ADC XB010
anti-5T4 antibody-drug conjugate XB010
anti-5T4/MMAE ADC XB010
Code name:XB 010
XB-010
XB010
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search